Life-threatening complications for diabetic patients taking SGLT2 inhibitors when undergoing surgery: A poorly recognised problem?

被引:0
作者
Sohatee, Mark [1 ]
Holland, James [1 ]
机构
[1] Newcastle Upon Tyne NHS Fdn Trust, Trauma & Orthopaed Dept, Newcastle Upon Tyne, Tyne & Wear, England
关键词
Risk management; Service improvement; Trauma and orthopaedic surgery; Post-anaesthetic care; Holistic care; Diabetes; CARDIOVASCULAR OUTCOMES; KETOACIDOSIS;
D O I
10.1177/17504589211024409
中图分类号
R61 [外科手术学];
学科分类号
摘要
A knowledge of perioperative problems and complications is an important requirement for surgeons. Diabetic patients are a particular group of patients that are specifically at risk of problems. These risks are not only related to the underlying pathophysiological process associated with the disease, but can also occur secondarily to medications used to manage the condition and require careful monitoring, and is of increased importance in the perioperative period. Although a number of medications have historically been used to manage diabetes, a relatively novel group of diabetic medications 'SGLT2 inhibitors' are now being used and have been shown to have many positive attributes, when considering the sequalae of diabetes. However, they have also been associated with significant perioperative problems, which are a consequence of euglycaemic ketoacidosis, a potentially life-threatening condition. Given the significant complications associated with these medications, it is important that practitioners should have an awareness of the problems related to their use. In addition, messages contained in safety releases pertaining to SGLT2 inhibitor use and their risks in patients undergoing surgery, may have been weakened due the timing of their publication in March 2020, during the first UK national lockdown amidst the Coronavirus pandemic.
引用
收藏
页码:234 / 238
页数:5
相关论文
共 33 条
[11]   SGLT2 inhibitor-induced euglycaemic diabetic ketoacidosis may be due to abrupt, severe and transient impaired glucose sensing in susceptible individuals with a hitherto unrecognised beta cell SGLT variant [J].
Finucane, F. M. .
MEDICAL HYPOTHESES, 2018, 114 :11-12
[12]  
GMC, 2018, TRAUM ORTHO SURG CUR
[13]   SGLT2 Inhibitor-associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis [J].
Goldenberg, Ronald M. ;
Berard, Lori D. ;
Cheng, Alice Y. Y. ;
Gilbert, Jeremy D. ;
Verma, Subodh ;
Woo, Vincent C. ;
Yale, Jean-Francois .
CLINICAL THERAPEUTICS, 2016, 38 (12) :2654-2664
[14]   Sodium-glucose linked transporter 2 inhibitor-associated perioperative euglycaemic diabetic ketoacidosis: a case for a perioperative guideline [J].
Hoffman, C. ;
Green, M. ;
Megafu, O. .
ANAESTHESIA AND INTENSIVE CARE, 2017, 45 (06) :758-759
[15]   An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus [J].
Hsia, Daniel S. ;
Grove, Owen ;
Cefalu, William T. .
CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2017, 24 (01) :73-79
[16]   Sodium-glucose Cotransporter-2 Inhibitors and Euglycaemic Diabetic Ketoacidosis in the Perioperative Period: Case Report [J].
Jhaveri, Urmita ;
Vardesh, Deepak .
CUREUS JOURNAL OF MEDICAL SCIENCE, 2019, 11 (08)
[17]  
Kerridge R, 2018, GOOD BAD UGLY SODIUM
[18]   Metabolic acidosis: pathophysiology, diagnosis and management [J].
Kraut, Jeffrey A. ;
Madias, Nicolaos E. .
NATURE REVIEWS NEPHROLOGY, 2010, 6 (05) :274-285
[19]   Euglycaemic diabetic ketoacidosis in a 43-year-old woman with type 2 diabetes mellitus on SGLT-2 inhibitor (empagliflozin) [J].
Latif, Azka ;
Gastelum, Aheli Arce ;
Sood, Akshat ;
Reddy, Joseph Thilumala .
BMJ CASE REPORTS, 2020, 13 (06)
[20]   Dapagliflozin (SGLT2-i) induced euglycaemic diabetic ketoacidosis [J].
Leader, Ross ;
Cowen, Jake ;
Rajeev, Surya Panicker .
BMJ CASE REPORTS, 2019, 12 (09)